SeaStar Medical (NASDAQ:ICU – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Analyst Recommendations
This is a breakdown of recent recommendations for SeaStar Medical and Aclarion, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SeaStar Medical | 1 | 0 | 1 | 0 | 2.00 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
SeaStar Medical presently has a consensus price target of $8.00, suggesting a potential upside of 172.11%. Aclarion has a consensus price target of $7.50, suggesting a potential upside of 110.08%. Given SeaStar Medical’s higher possible upside, equities analysts clearly believe SeaStar Medical is more favorable than Aclarion.
Volatility & Risk
Institutional & Insider Ownership
1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by company insiders. Comparatively, 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares SeaStar Medical and Aclarion”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SeaStar Medical | $1.23 million | 9.56 | -$12.15 million | ($4.80) | -0.61 |
| Aclarion | $80,000.00 | 109.78 | -$7.23 million | ($9.03) | -0.40 |
Aclarion has lower revenue, but higher earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SeaStar Medical and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SeaStar Medical | -828.62% | -146.29% | -96.48% |
| Aclarion | -10,320.51% | -54.41% | -51.71% |
Summary
Aclarion beats SeaStar Medical on 7 of the 12 factors compared between the two stocks.
About SeaStar Medical
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
